Leptomeningeal Metastases of Breast Cancer: Toward New Therapies

Abstract

Leptomeningeal metastases (LM) are growths of breast cancer in the linings of the brain and spinal cord and/or in the cerebrospinal fluid (CSF). LM represent 11-20% of central nervous system (CNS) metastases. They are prevalent in younger patients. LM occur in all subclasses of breast cancer and are currently treated with intrathecal (IT) methotrexate or liposomal cytarabine or radiation therapy. Although 68% of patients initially responded to chemotherapy treatment, median overall survival was 18 weeks, resulting from LM progression. Severe complications arise from LM. There is an urgent need for research into this devastating form of breast cancer progression to identify new potential preventives and treatments. Despite an ongoing partial shutdown due to Covid19, we have made significant progress in deriving models for leptomeningeal invasion (LI).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1162381

Entities

People

  • Patricia Steeg

Organizations

  • Geneva Foundation

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Brain
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cells
  • Central Nervous System
  • Diseases And Disorders
  • Lung Cancer
  • Medical Personnel
  • Meninges
  • Metastasis
  • Neoplasms
  • Nervous System
  • Oncology
  • Spinal Column
  • Spinal Cord
  • Therapy

Fields of Study

  • Medicine

Readers

  • Molecular and Cellular Biochemistry
  • Neurotrauma and Rehabilitation Medicine.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.